SubHero Banner
Text

Erbitux® (cetuximab) – New indication

September 28, 2021 - Eli Lilly announced the FDA approval of Erbitux (cetuximab), in combination with Braftovi® (encorafenib), for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Download PDF